MCID: HPT021
MIFTS: 75

Hepatitis

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 38 12 76 29 55 6 43 44 15 73
Chronic Persistent Hepatitis 12 55 73
Acute Hepatitis 12 29 73
Hepatitis, Chronic 44 73
Chronic Hepatitis 12 15
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Hepatitis Chronic 55
Hepatitis, Animal 73
Animal Hepatitis 12
Hepatitis a 73

Classifications:



Summaries for Hepatitis

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. Viruses cause most cases of hepatitis. The type of hepatitis is named for the virus that causes it; for example, hepatitis A, hepatitis B or hepatitis C. Drug or alcohol use can also cause hepatitis. In other cases, your body mistakenly attacks healthy cells in the liver. Some people who have hepatitis have no symptoms. Others may have Loss of appetite Nausea and vomiting Diarrhea Dark-colored urine and pale bowel movements Stomach pain Jaundice, yellowing of skin and eyes Some forms of hepatitis are mild, and others can be serious. Some can lead to scarring, called cirrhosis, or to liver cancer. Sometimes hepatitis goes away by itself. If it does not, it can be treated with drugs. Sometimes hepatitis lasts a lifetime. Vaccines can help prevent some viral forms.

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to hepatitis d and hepatitis b, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatitis is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Hepatitis C and Jak-Stat Signaling Pathway (sino). The drugs Intron A and Synercid I.V. have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes, and related phenotype is mortality/aging.

Wikipedia : 76 Hepatitis is inflammation of the liver tissue. Some people have no symptoms whereas others develop... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2166)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 34.2 GPT IFNA2
2 hepatitis b 33.8 AFP ASGR2 GPT IFNA1 IFNA2 IFNAR2
3 hepatitis a 33.7 AFP GPT HAVCR1 HAVCR2 SEPSECS
4 autoimmune hepatitis 33.7 GPT KRT8 SEPSECS
5 hepatitis c 33.6 CD81 CLDN1 GPT IFNA1 IFNA2 IFNAR2
6 viral hepatitis 33.6 AFP GPT IFNA1 IFNA2 KRT18 SEPSECS
7 hepatitis c virus 33.5 CD81 CLDN1 GPT HAVCR2 IFNL4 KRT18
8 liver disease 32.7 AFP GPT IFNA1 KRT18 KRT8 SEPSECS
9 liver cirrhosis 32.2 AFP GPT IFNA1 KRT18 KRT8
10 viral infectious disease 31.9 CD81 GPT IFNA1 IFNA2
11 cryoglobulinemia, familial mixed 31.1 IFNA1 IFNA2
12 nonalcoholic steatohepatitis 30.9 GPT KRT18
13 cryptogenic cirrhosis 30.1 KRT18 KRT8
14 opisthorchiasis 30.0 AFP GPT
15 transitional cell carcinoma 29.4 IFNA2 KRT18 KRT8
16 discoid lupus erythematosus 29.1 IFNA1 IFNA2
17 lymphoepithelioma-like carcinoma 29.0 KRT18 KRT8
18 hepatic veno-occlusive disease 12.6
19 hepatic venoocclusive disease with immunodeficiency 12.5
20 hepatic lipase deficiency 12.5
21 alcoholic hepatitis 12.5
22 hepatic encephalopathy 12.5
23 hepatitis e 12.4
24 congenital hepatic fibrosis 12.4
25 hepatic adenomas, familial 12.3
26 non-a-e hepatitis 12.3
27 renal-hepatic-pancreatic dysplasia 12.3
28 drug-induced hepatitis 12.3
29 porphyria, acute hepatic 12.3
30 epstein-barr virus hepatitis 12.2
31 renal-hepatic-pancreatic dysplasia 2 12.2
32 hepatic fibrosis, severe due to schistosoma mansoni infection 12.2
33 granulomatous hepatitis 12.2
34 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.2
35 hepatic coma 12.2
36 hepatic flexure cancer 12.1
37 renal-hepatic-pancreatic dysplasia 1 12.1
38 hepatic tuberculosis 12.1
39 fulminant viral hepatitis 12.1
40 hepatic infarction 12.1
41 halothane hepatitis 12.1
42 hepatic angiomyolipoma 12.1
43 acute liver failure 12.1
44 hepatitis b vaccine, response to 12.1
45 sclerosing hepatic carcinoma 12.0
46 hepatic vascular disease 12.0
47 hepatocellular carcinoma 12.0
48 coach syndrome 12.0
49 primary hepatic neuroendocrine carcinoma 12.0
50 isolated congenital hepatic fibrosis 12.0

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Chronic Myocardial Ischemia
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Hypothyroidism
Ischemic Heart Disease Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:



Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, hepatosplenomegaly, lameness, animal, icterus, dyspepsia, heartburn, gastrointestinal gas, hepatocellular jaundice

MGI Mouse Phenotypes related to Hepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.4 AFP ASGR2 CLDN1 HAVCR2 IFNAR2 KRT18

Drugs & Therapeutics for Hepatitis

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
2
Synercid I.V. 18 DALFOPRISTIN; QUINUPRISTIN QUINUPRISTIN; DALFOPRISTIN Rhone Poulenc Rorer September 1999
3
Cefazolin and Dextrose USP 18 CEFAZOLIN SODIUM B Braun Medical July 2000

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 870)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
2
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
3
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
6
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
7
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
8
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
9
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 99210-65-8, 215647-85-1
10
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
11
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
12
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
13
Rifampicin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
14
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
15
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
16
Tocopherol Approved, Investigational Phase 4,Phase 3,Not Applicable 1406-66-2 14986
17
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
18
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
19
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
20
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
21
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
22
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
23
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
24
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
25
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
26
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-24-8 5755
28
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 302-25-0
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 83-43-2 6741
30
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 2921-57-5
31
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
32
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 174722-31-7 10201696
33
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
34
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
35
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
36
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 8008-53-5
37
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
38 tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6493-05-6 4740
40
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 2713 9552079
41
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 128-13-2 31401
42
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 149351 5280723
43
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
44
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2 1405-86-3 3495
45
Simvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 79902-63-9 54454
46
Insulin glulisine Approved Phase 4 207748-29-6
47
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6
48
Insulin Glargine Approved Phase 4 160337-95-1
49
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
50
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158

Interventional clinical trials:

(show top 50) (show all 4617)
# Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
3 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients Unknown status NCT02963714 Phase 4
4 Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients Unknown status NCT02991599 Phase 4
5 Immunogenicity of Hepatitis B Vaccination Among Drug Users Unknown status NCT02959775 Phase 4
6 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
7 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
8 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
9 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
10 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
11 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
12 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
13 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
14 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
15 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
16 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
17 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
18 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
19 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
20 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
21 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
22 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
23 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
24 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
25 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
26 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
27 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
28 Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
29 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
30 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
31 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
32 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
33 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
34 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
35 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
36 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
37 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
38 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
39 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
40 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
41 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
42 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
43 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
44 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
45 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
46 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
47 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
48 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
49 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
50 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera� HepaStem, human adult liver progenitor cells for liver diseases
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 19091822 24142276 22900053

Cochrane evidence based reviews: hepatitis

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

# Genetic test Affiliating Genes
1 Acute Hepatitis 29
2 Hepatitis 29

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

41
Liver, T Cells, Testes, Kidney, B Cells, Bone, Thyroid

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 27824)
# Title Authors Year
1
Acute Alcoholic Hepatitis. ( 30454835 )
2019
2
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
3
Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection. ( 30480811 )
2019
4
Editorial: comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C. ( 30548317 )
2019
5
Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C - authors' reply. ( 30548320 )
2019
6
Chylomicron mimicking solid lipid nanoemulsions encapsulated enteric minicapsules targeted to colon for immunization against hepatitis B. ( 30503974 )
2019
7
The effect of rupture of membranes and labour on the risk of hepatitis B vertical transmission: Prospective multicentre observational study. ( 30504033 )
2019
8
T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. ( 30518547 )
2019
9
Pharmacy-led hepatitis C treatment pathways to help ensure elimination. ( 30527577 )
2019
10
Hepatitis C incidence 3 years after implementation of an educate, test, and treat programme in an Egyptian village. ( 30527578 )
2019
11
Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. ( 30527582 )
2019
12
Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. ( 30467877 )
2019
13
Strategies for access to affordable hepatitis C testing and treatment in Asia. ( 30480583 )
2019
14
HIV/tuberculosis/hepatitis C virus services for incarcerated populations in Azerbaijan and the Eastern Europe Central Asia region. ( 30489347 )
2019
15
A hepatitis B vaccine booster shot at age 10 could be cost-saving in China: But is it too soon to tell? ( 30448390 )
2019
16
Acquisition rate of antibody to hepatitis B surface antigen among medical and dental students in Japan after three-dose hepatitis B vaccination. ( 30449632 )
2019
17
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. ( 30450681 )
2019
18
The Revolution in Treatment of Hepatitis C. ( 30466675 )
2019
19
Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. ( 30466898 )
2019
20
Core gene insertion in hepatitis B virus genotype G functions at both the encoded amino acid sequence and RNA structure levels to stimulate core protein expression. ( 30415131 )
2019
21
Peroxisome proliferator-activated receptor γ coactivator family members competitively regulate hepatitis b virus biosynthesis. ( 30419515 )
2019
22
TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. ( 30421643 )
2019
23
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. ( 30394948 )
2019
24
Characterization of a quasi-enveloped, fast replicating hepevirus from fish and its use as hepatitis E virus surrogate. ( 30399394 )
2019
25
Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. ( 30401643 )
2019
26
Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis. ( 30215232 )
2019
27
Prevalence of Hepatitis B Virus (HBV) Among Blood Donors in Eastern Saudi Arabia: Results From a Five-Year Retrospective Study of HBV Seromarkers. ( 30215234 )
2019
28
Performance Evaluation of the Beckman Coulter DxN VERIS Hepatitis B Virus (HBV) Assay in Comparison With the Abbott RealTime HBV Assay. ( 30215235 )
2019
29
Hyperbranched rolling circle amplification (HRCA)-based fluorescence biosensor for ultrasensitive and specific detection of single-nucleotide polymorphism genotyping associated with the therapy of chronic hepatitis B virus infection. ( 30262063 )
2019
30
Serum miR-21 and miR-26a Levels Negatively Correlate with Severity of Cirrhosis in Patients with Chronic Hepatitis B. ( 30147020 )
2019
31
Hepatitis B virus and hepatitis delta virus subtypes circulating in Algeria and seroprevalence of HDV infection. ( 30168584 )
2019
32
Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study. ( 30080685 )
2019
33
Aberrant DNA methylation profile of hepatitis B virus infection. ( 30118556 )
2019
34
Impact of an electronic medical record reminder on hepatitis B vaccine initiation and completion rates among insured adults with diabetes mellitus. ( 29958736 )
2019
35
Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. ( 30239347 )
2019
36
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. ( 30247174 )
2019
37
Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients. ( 30133717 )
2019
38
Human pegivirus isolates characterized by deep sequencing from hepatitis C virus-RNA and human immunodeficiency virus-RNA-positive blood donations, France. ( 30133782 )
2019
39
No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. ( 30142097 )
2019
40
Skeletal muscle mass depletion in patients with hepatitis C virus infection. ( 30179904 )
2019
41
Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. ( 30199473 )
2019
42
Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay. ( 30091789 )
2019
43
Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. ( 30024489 )
2019
44
Design and Development of Modified mRNA Encoding Core Antigen of Hepatitis C Virus: a Possible Application in Vaccine Production ( 30056690 )
2019
45
Evidence of hepatitis E virus infections among persons who use crack cocaine from the Midwest region of Brazil. ( 30133759 )
2019
46
Human hepatitis E virus circulation in Bulgaria: Deep Bayesian phylogenetic analysis for viral spread control in the country. ( 30168583 )
2019
47
Hepatitis E seroprevalence in the United States: Results for immunoglobulins IGG and IGM. ( 30168589 )
2019
48
Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. ( 29354656 )
2018
49
Old and New Treatments for Pediatric Autoimmune Hepatitis. ( 29766815 )
2018
50
Rapid Remission of Graves' Hyperthyroidism Without Thionamides Under Immunosuppressive Treatment for Concomitant Autoimmune Hepatitis. ( 29336235 )
2018

Variations for Hepatitis

ClinVar genetic disease variations for Hepatitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh37 Chromosome MT, 3275: 3275
2 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh38 Chromosome MT, 3275: 3275

Copy number variations for Hepatitis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

Pathways related to Hepatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.22 CD81 CLDN1 IFNA1 IFNA2 IFNAR2 SCARB1
2 11.08 IFNA1 IFNA2 IFNAR2
3 10.64 LMBRD1 SCARB1
4
Show member pathways
10.52 IFNA2 IFNAR2

GO Terms for Hepatitis

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.71 ASGR2 CD81 IFNA2 IFNAR2
2 T cell activation involved in immune response GO:0002286 9.48 IFNA1 IFNA2
3 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.46 IFNA1 IFNA2
4 defense response to virus GO:0051607 9.46 IFNA1 IFNA2 IFNAR2 IFNL4
5 natural killer cell activation involved in immune response GO:0002323 9.43 IFNA1 IFNA2
6 type I interferon signaling pathway GO:0060337 9.43 IFNA1 IFNA2 IFNAR2
7 hepatocyte apoptotic process GO:0097284 9.37 KRT18 KRT8
8 protein localization to lysosome GO:0061462 9.32 CD81 LAMTOR5
9 viral entry into host cell GO:0046718 9.26 CD81 CLDN1 HAVCR1 SCARB1
10 viral process GO:0016032 9.17 CD81 CLDN1 HAVCR1 KRT18 KRT8 LMBRD1

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA1 IFNA2
2 type I interferon receptor binding GO:0005132 8.96 IFNA1 IFNA2
3 virus receptor activity GO:0001618 8.92 CD81 CLDN1 HAVCR1 SCARB1

Sources for Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....